WASHINGTON (AP) — Federal regulators are challenging patents on 20 brand name drugs, including the blockbuster weight-loss injection Ozempic, in the latest action by the Biden administration targeting industry practices that drive up pharmaceutical prices.
The Federal Trade Commission on Tuesday sent warning letters to 10 drugmakers, taking issue with patents on popular drugs for weight loss, diabetes, asthma and other reparatory conditions. The letters allege that certain patents filed by Novo Nordisk, GlaxoSmithKline, AstraZeneca and seven other companies are inaccurate or misleading.
Brand-name drugmakers use patents to protect their medicines and stave off cheaper, generic medicines. Most blockbuster drugs are protected by dozens of patents covering various ingredients, manufacturing processes and intellectual property. Generic drugmakers can only launch their own cheaper versions if the patents have expired or are successfully challenged in court.
Related articles:
Related suggestion:
Wisconsin GOPNorth Carolina bill to curb maskInnovation, investment urged to win global AI raceEPL says Everton still 'in discussions' with 777 as scrutiny ramps up on US firmTennessee governor OKs bill allowing death penalty for child rape convictionsAP weekly sports photo gallerySea along the south of England including at Brighton beach goes brown due to algal bloomWisconsin GOPFormer University of Missouri frat member pleads guilty in hazing that caused brain damageChinese books, cultural products welcomed at int'l book fair in Morocco
3.3823s , 6501.671875 kb
Copyright © 2024 Powered by US challenges 'bogus' patents on Ozempic and other drugs in effort to spur competition ,Global Gleam news portal